Introduction
Dental implants are a reliable treatment choice for rehabilitation of partially or completely edentulous patients 1 . On the basis of the implant failure factors that have been proposed, i.e. clinical or/and radiographic findings that require implant extraction-pain or mobility during clinical examination or periimplant radiolucency in dental x-rays 2 , the success rate of dental implantation surpasses 90% during a 10-year-observation period 3 .
This high success rate generally refers to subjects with unremarkable medical history. On the other hand, medically compromised subjects, with systemic diseases such as diabetes mellitus, osteoporosis, cardiovascular Data retrieved included number of patients, patients' demographics, history of autoimmune disorders, oral manifestations, number of inserted implants and type of prosthodontic restoration, implants success rate and follow-up period. Implants were considered as successful in case there was no need for removal at the study end point; thus, the implant success rate coincided with the survival rate. In cases with oral carcinoma development, information about the time interval between the placement of implants and cancer diagnosis, the site and clinical presentation of cancer, prior positive oral cancer history and smoking habits were also recorded. Studies regarding dental implants in patients with de novo oral cancer, i.e. without history of oral mucosal disease, were excluded.
Results
The literature review yielded 50 studies with regards to dental implants in patients with oral mucosal diseases; in particular, 14 studies referred to OLP 13, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , 11 studies to EB 15, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , 1 study to pemphigus vulgaris 40 , 14 studies to SS [11] [12] [13] [14] 21, [41] [42] [43] [44] [45] [46] [47] [48] [49] , 11 studies to systemic sclerosis 13, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , 3 studies to systemic lupus erythematosus (SLE)14 29, 44 and 5 studies to oral SCC development associated with leukoplakia 27, [58] [59] [60] [61] . Five studies presented patients with more than one oral mucosal disease 13, 21, 27, 29, 48 . Studies regarding dental implants in patients with cicatricial or bullous pemphigoid, as well as in patients with leukoplakia that did not progress into oral malignancy, were not identified.
Oral Lichen Planus
Our review identified 14 studies from the English literature with 87 OLP patients (63 females and 24 males, female to male ratio: 2.63:1) who have received more than 313 dental implants 13, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . In 3 patients information on the number of implants inserted was not available 27 . In particular, 9 case reports 13, [19] [20] [21] [22] 25, 26, 28, 29 , 3 retrospective studies 18, 24, 27 and 2 prospective controlled studies 17, 23 were retrieved. In the majority of the patients, OLP was diagnosed prior to implants' insertion 13, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] ; in two studies implants were placed before and after the diagnosis of OLP 18, 25 , while in two studies information regarding to exact time of implant insertion was missing 27, 29 . One OLP patient also suffered from SS 21 and another from SLE 29 . At the time of first examination OLP type was predominantly reticular or plaque-type in 19 (21.8%) patients, erosive or atrophic in 38 (43.7%) patients and unspecified in 30 (34.5%) patients (Table  1) . In 32 cases with available information on the intraoral site of OLP lesions, the buccal mucosa and the gingiva were mainly involved, followed by the tongue and palate (Table 1 ). In 9 patients OLP lesions were noticed in close proximity to the dental implants 18, 24 . Desquamative disease, immunosuppression etc. were considered to be at an increased risk for implant placement and a number of relative and absolute contraindications have been suggested [4] [5] [6] .
Recently, investigators have proposed that head and neck radiotherapy at a dose > 50Gy, intravenous bisphosphonates therapy and chronic systemic treatment with hormonal agents, corticosteroids or immunosuppressive drugs may be considered to be contraindications for implant placement 7 . Other studies have stated that positive history for hepatitis, cardiovascular diseases, rheumatic disorders and osteoporosis are significantly associated with increased rates of implant failure. However there is no consensus on those issues, which still remain controversial 8, 9 . Therefore nowadays, the spectrum of indications for dental implants in medically compromised patients has undergone many modifications and has been widened.
In addition to the impact of systemic diseases, the possible effect of oral mucosal diseases on the successful rehabilitation with dental implants has attracted increasing interest during the last decade 1, 10 . The oral mucosal soreness observed in several mucocutaneous diseases and the oral dryness in patients with autoimmune disorders, such as Sjögren's syndrome (SS) or lupus erythematosus, complicates the proper oral hygiene and predisposes to increased dental caries, periodontal disease and infections leading to further tooth loss [11] [12] [13] . Except for the oral mucosal fragility and xerostomia in those subjects, patients with rare diseases, such as epidermolysis bullosa (EB) and scleroderma, are characterized by various oral complications, e.g. blisters, tissue scars, induration and microstomia, which hinder the use of removable dentures and render dental implants not only a promising therapeutic solution, but occasionally the single treatment of choice 12, [14] [15] [16] .
The aim of the present study is to review the pertinent literature regarding the dental implant treatment prospects for patients with oral mucosal diseases.
Materials and Methods
PubMed and Google Scholar electronic databases were searched in April 2017 with the following key words: dental implants, oral mucosal diseases, oral lichen planus (OLP), EB, SS, cicatricial pemphigoid, bullous pemphigoid, pemphigus vulgaris, scleroderma/ systemic sclerosis, lupus erythematosus, leukoplakia, oral premalignant lesions, oral cancer, oral squamous cell carcinoma (SCC). Only studies from the English literature were selected. Prospective or retrospective clinical studies, case studies or case-reports were included in the current analysis. Review papers were excluded. insertion and oral cancer development was unspecified 29 . Three OLP subjects with SCC were smokers 19, 27 , 2 had a history of oral cancer 22, 27 and one had been also diagnosed with oral leukoplakia 27 . Dental implants in close proximity to the oral malignancy were removed 19, 22, 26, 27 . In contrast, 244/288 implants survived in 79 OLP patients without SCC development during a follow up period ranging from 21 months to 13 years (success rate = 84.7%) 13, 17, 18, 21, [23] [24] [25] 28 . Two implants failed in a patient with bruxism 32 and 60 months after their insertion 20 , while 42 implants were lost in 20 patients with active OLP within the first year of their placement 17 . These 42 implants were replaced with absolute success for a 3-year-observational period 17 .
gingivitis was reported in 16 subjects 23, 24 . In symptomatic OLP cases, a steroid-based therapy either topical or systemic usually preceded implants insertion 17, 18, [21] [22] [23] 26 . Moreover, disease exacerbations during the postoperative and the follow-up period were managed with topical corticosteroids, antifungal agents or retinoids 18, 21, 23, 24 . The type of prosthodontic restoration was reported in 73/87 (83.9%) OLP patients and in the majority of the cases (64/73, 87.7%) represented a fixed prosthesis 13, 17, 19, [23] [24] [25] [26] [27] [28] [29] .
Among 87 OLP patients with dental implants, 8 women (9.2%) developed oral SCC, which presented as a mandibular exophytic mass; two of them within the first year following implant insertion 27 and four 3 19, 22 or 4 years 26, 27 post-insertion. In two patients the interval between implant 35, 37 were used in 22 and 7 patients, respectively, while in five subjects with atrophic jaws implants were inserted simultaneously with bone grafts 31, 38 . During an observational period ranging from 1 to 9 years, 177/180 (98.3%) implants were successfully retained ( Table 2) .
Epidermolysis Bullosa
The first case of dental implants in EB patients was published 37 38, 39 ) could be disclosed reporting rehabilitation of 29 EB patients (19 females, 9 males, 1 gender not specified) with 180 dental implants. EB patients exhibited multiple bleeding blisters or ulcers, ankyloglossia, In contrast to OLP and EB, literature data on dental implants in patients with other mucocutaneous disorders are scarce. Literature review yielded only one case report of a female patient with pemphigus vulgaris, medicated with systemic corticosteroids and azathioprine, who had received two implants and has been successfully followed up for 32 months 40 . No case regarding dental implants in patients with cicatricial or bullous pemphigoid has been found in the literature.
Sjögren's Syndrome
Implant rehabilitation in a SS patient was initially reported 62 in 1993 and since then more than 428 dental implants have been placed in 115 SS subjects (105 females, 5 males, 5 gender not specified), documented by 10 case-reports 11, 13, 14, 21, [41] [42] [43] [44] [45] [46] , 3 retrospective studies 12, 48, 49 and 1 observational cohort study 47 . In one study, information on the number of implants inserted was not available 42 . Forty seven (40.9%) patients were diagnosed with primary SS 12, 13, 21, 41, 45, 46 , one of whom also suffered from OLP 21 . Dental implants were also placed in thirty in 12 studies involving 81 SS subjects; in particular, fixed prostheses were selected in 6 studies 14, 41, [43] [44] [45] [46] , removable overdentures in 1 study 21 and both prosthodontic restoration types were used in 5 studies [11] [12] [13] 48, 49 . Of the 407 dental implants with available survival rates, 22 failed during a follow-up period ranging from 1 to 13 years, corresponding to a success rate of 94.6 % ( 
Systemic Lupus Erythematosus
Limited literature data exist regarding dental implants in SLE patients. Ergun et al. 44 reported the successful placement of six dental implants in a patient with dry mouth, diagnosed with SLE and SS, who was followed for 2 years. Moreover, one OLP patient treated with dental implants had a positive history for SLE and ultimately developed a mandibular SCC 29 .
Systemic Sclerosis
Eleven studies (9 case reports 13,50-57 and 2 retrospective studies 48, 49 ) reported rehabilitation of 11 systemic scleroderma patients (6 females, 1 male, 4 with unknown gender) with more than 61 dental implants. Microstomia, difficulty in mastication, root resorptions and advanced periodontal disease were observed in most patients [50] [51] [52] [53] [54] [55] 57 . Five patients suffered from systemic sclerosis alone [50] [51] [52] [53] 55 , overdentures 13, 53, 56 . Forty one out of 42 dental implants in 6 patients with known outcome 13, 48, 49, 52, 56, 57 were successfully followed up for a period of 2 to 5 years (success rate= 97.6%, Table 4 ). one was diagnosed with concomitant SS 13 , one with SS and RA 48 , whereas in 4 cases there was no information 13, 48, 49, 56 . Eight scleroderma patients were rehabilitated with a fixed implant-supported prosthesis [48] [49] [50] [51] [52] 54, 55, 57 and three with 
Leukoplakia/Oral SCC
The review of the pertinent literature revealed 16 patients with clinically diagnosed leukoplakia who had developed SCC in the vicinity of dental implants (9 females, 7 males, female to male ratio= 1.3:1; age range= 42-88 years, mean age= 69.4 years) 27, [58] [59] [60] [61] . In 14/16 patients implant rehabilitation was established with removable prostheses 27, 58, 59 , in one subject with a fixed prosthesis 61 , while in one case information regarding prosthodontic restoration was missing 60 . Twelve out of the 16 subjects (75%) had a positive history of oral cancer (Table 5) . At the time of periimplant carcinoma diagnosis, 5/16 (31.3%) patients were current smokers, 3/16 (18.6%) past smokers, 4/16 (25%) non-smokers, whereas data about smoking habits were missing in 4 (25%) cases (Table 5) . Periimplant cancer predominantly involved the mandible (15/16-93.6% cases), mainly as an exophytic mass or gingival hyperplasia mimicking periimplantitis, and less often as an ulcer (Table 5) . 60 1 F 77 NA NA ex man no yes Abbreviations: SCC, squamous cell carcinoma; F, female; M, male; NA, not available; ex, exophytic mass; man, mandible; max, maxilla implant restoration in SS subjects has shown favorable results. According to a retrospective study evaluating the implant outcome in SS patients and healthy controls, the survival rates of dental implants, the incidence of periimplant mucositis, periimplantitis and several periimplant clinical indices (bleeding index, plaque index etc.), were comparable between the two groups 12 . A subsequent observational cohort study provided similar results 47 . According to the reviewed literature, in the present study no significant differences in the implant survival rates between patients with primary or secondary SS associated with other autoimmune disorders, could be detected, which is in accordance with previous reports 12 . Data on dental implants in patients with other autoimmune diseases, including pemphigus vulgaris, SLE or pemphigoid, as well as in patients with leukoplakia without malignant transformation are scarce or missing 29, 40, 44 . In contrast, implants have been evaluated in patients with rare disorders involving oral mucosa, such as EB and systemic sclerosis 10 . The severe microstomia, which is a common complication of both aforementioned diseases, and the tendency for blister formation after minor trauma seen in EB, cause significant difficulties in the use of conventional prostheses and, therefore, stress the need of a therapeutic alternative.
Despite the small number of patients treated, literature favors dental implantation in EB subjects 15, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Precautionary measures during implant surgery in EB patients include lubrication of lips and intraoral tissues with petroleum jelly and close contact of the aspirator with the bone rather than the mucosa. Local anesthesia is preferable versus general to avoid intubation-induced ulcers and should be performed slowly and deeply into the oral soft tissues to reduce the risk of blistering 30, 31, [35] [36] [37] 39 . Bone grafting simultaneously to implant placement is effective in case of severe jaw atrophy 31, 38 and fixed prostheses are preferred compared to overdentures 35 in order to avoid irritation of the fragile oral mucosa during mastication 37 .
Dental implants have also been considered a viable therapeutic solution in patients with systemic sclerosis, who have difficulty to handle and tolerate the removable dentures, because of limited mouth opening and finger deformities 52, 53, 55 . Implant-supported prostheses contribute decisively to the improvement of function, aesthetics and sociability of these patients 50 . In particular, implant placement in the anterior maxillary and mandibular portion between the canines is indicated to ensure stability of the prosthetic restoration and the improvement of facial aesthetics 67 . However, due to the scarce literature on dental implantation in scleroderma subjects, and the lack of detailed information on the observational period and the success rates 13, [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] , further studies are warranted to propose specific treatment recommendations 50 .
Discussion
The present study summarizes the current evidence regarding dental implantation in patients with oral mucosal diseases. It was interesting to note that the number of studies available on this topic is constantly increasing which can be possibly explained by the functional, esthetic, and psychological benefits that these patients experience, which urge investigators to explore the implant treatment prospects in this group of individuals.
OLP and SS represent the two disease entities that have been more extensively investigated so far 10, 14, 63 , although concerns have been raised in the past about the long-term success of dental implantation in those patients. It has been speculated that the health of the periimplant tissues in OLP patients may be compromised by the impaired attachment of the oral epithelium to the titanium surface, leading to a defective mucosal block to microorganisms 64 . Moreover, it has been suggested that upregulated pro-inflammatory cytokines induced by oral epithelial cells in OLP subjects stimulate resorption of the periimplant alveolar bone 65, 66 . In contrast, the current literature seems to encourage dental implantation in OLP patients. According to three studies which compared the outcome of dental implants between OLP subjects and healthy controls 18, 23, 24 , no difference was detected between the two groups in terms of implant stability and development of periimplant mucositis or periimplantitis. These findings suggest that the disease severity or the intraoral site of involvement do not seem to affect the survival of dental implants 18, 23, 24 . However, detailed description of the clinical forms of the disease and information on the site affected is missing in several studies. Furthermore the number of cases with desquamative gingivitis 23, 24 is quite small or information on implant placement adjacent to OLP lesions 18, 24 is scarce and thus a protocol on clinical management of these cases cannot be established. Dental implants should not be inserted during the acute phase of the disease 17, 23 and caution should be exercised in patients with parafunctional habits, due to an increased risk for failure 20 . Treatment with topical (e.g. clobetasol propionate mouthwashes or ointment, dexamethasone, triamcinolone acetonide) or systemic corticosteroids (e.g. oral prednisone) should precede the placement of implants in symptomatic OLP cases and medication should be re-implemented in case of exacerbations during the follow-up period 17, 18, 21, 23 . Long term systemic steroid therapy, although rare, may lead to immunosuppression and subsequently interfere with the mucosal healing capacity 18 .
The long-term survival of dental implants in SS patients has been previously challenged by the disturbed immune response caused by the disease itself and the chronic immunosuppressive therapy 4 . However, to date, Patients with oral potential malignant disorders, such as leukoplakia and OLP, are at risk for cancer development. Prior to case selection for implant therapy, factors, e.g. tobacco or alcohol consumption, should be modified 68 . Short-interval follow-up examinations are crucial after implant rehabilitation to early detect possible malignant transformation 68, 69 . Implant-supported prostheses should be regularly removed in order to clinically evaluate the periimplant soft tissues and, thus, fixed prostheses should be selected with caution, especially in patients with a positive history of cancer and risk for recurrence 27, 61 . A carcinoma adjacent to dental implants may manifest as an exophytic mass mimicking an inflammatory reactive lesion of the gingivae or periimplantitis 27, 58 , and efforts to manage through periodontal treatment may cause delay in diagnosis 59 . Thus, tumors and ulcers arising in the proximity of dental implants, resistant to conventional therapeutic measurements, should be biopsied and submitted to histopathological examination 27, 59, 69 .
Conclusion
In conclusion, based on the reviewed literature, dental implants represent an acceptable and reliable treatment option with a high success rate in patients with chronic mucocutaneous diseases and autoimmune diseases with oral manifestations. However, further well-designed prospective studies, with long meticulous follow-up, are required to define treatment guidelines and recommendations and predict with accuracy the implant outcome in this group of patients.
Note:
The results of this paper were presented as a part of an invited lecture at the 22 nd BaSS Congress.
